查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840573

直接抗病毒市場（按產品類型、藥物類別、分銷管道和最終用戶分類）—2025-2032 年全球預測

Direct-acting Antiviral Drug Market by Product Type, Therapeutic Class, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

直接抗病毒藥物市場預計到 2032 年將成長至 339.2 億美元，複合年成長率為 13.65%。

主要市場統計數據
基準年2024年 121.8億美元
預計2025年 138.7億美元
預測年份：2032年 339.2億美元
複合年成長率（%） 13.65%

將直接抗病毒療法的臨床、操作和商業性基礎具體化，以支持醫療保健相關人員的策略決策

直接抗病毒藥物的出現永久重塑了我們對病毒性肝病和感染疾病的管理方法，顯著改善了患者的預後，並重新定義了對根治性治療途徑的期望。本簡介提供了這些治療方法的臨床和商業性背景，重點介紹了作用機制的創新、不斷發展的治療層級以及對醫療保健系統的更廣泛影響。本簡介也總結了近期的臨床進展，其中更短的療程、更高的耐受性和全基因型活性正在改變治療模式，並加速了專家臨床醫生的採用。

從供應鏈角度來看，生產複雜性和原料藥採購已成為開發商和採購商共同關注的關鍵因素。因此，品質源於設計的生產、生物製藥製程控制以及策略性供應商關係對於確保可預測的產品供應正變得越來越重要。同時，付款方的觀點也不斷演變，更注重長期療效和醫療成本節約，進而影響處方決策和合約簽訂策略。

由於診斷整合、治療合作計劃和分散護理模式將在未來塑造直接抗病毒藥物的臨床部署，本介紹透過概述臨床療效、營運部署、監管監督和商業性執行之間的相互關係來建構以下部分，領導者在將專案從開發推進到常規臨床實踐時必須協調這些關係。

臨床突破、分銷創新和監管調整如何融合，重新定義抗病毒療法的治療途徑和商業策略

隨著臨床進展與醫療保健服務和商業策略的變化相融合，直接抗病毒藥物領域正在經歷加速的轉型。治療方案正從漸進式改善轉變為對治癒率和治療便利性的根本性不同預期，這促使相關人員重新評估標準治療途徑和人群層面的根除策略。同時，藥理學的進展，尤其是組合方案，正在改變臨床試驗設計和終點選擇，從而為監管核准和產品說明書擴展提供更高效的途徑。

同時，分銷格局也在經歷結構性變革。數位醫療平台和遠端醫療降低了診斷和治療的門檻，使早期療育成為可能，並擴大了三級醫療機構以外可治療的患者群體。這種轉變正在推動診斷開發商、專科診所和社區醫療服務提供者之間更緊密的合作，並要求製造商採用更靈活的商業化模式，以支持不同醫療機構的教育、依從性和監測。

法律規範也進行了調整，更加重視真實世界證據和上市後監測，以監測更廣泛人群的長期療效和安全性。隨著這些變革力量的持續互動，製造商、付款人和相關人員將面臨機會和挑戰。積極主動地將臨床開發與可擴展交付模式相結合的相關人員將最有可能充分發揮下一代直接抗病毒療法的內在價值。

評估近期貿易政策和關稅發展如何改變抗病毒治療供應鏈的彈性、籌資策略和採購慣例

關稅徵收和貿易政策調整對醫藥供應鏈、籌資策略和貿易經濟（包括臨床可及性和生產規劃）產生了連鎖反應。關稅相關成本影響了活性藥物原料藥和輔料的採購選擇，迫使製造商多元化供應商、重新定位區域生產基地並重新配置庫存緩衝。這些商業應對措施不僅僅是戰術性的；它們會改變產品上市前置作業時間，限制應對力，並使與大型機構和政府買家的合約談判變得複雜。

此外，關稅與監管和品質要求相互影響，使採購決策更加複雜。當受關稅影響地區的供應商也擁有監管部門的核准或專業製造能力時，企業將面臨成本、合規性和上市速度之間的權衡。為此，企業擴大尋求區域製造夥伴關係、清關安排和垂直整合，以降低此類風險。同時，採購組織和付款方正在重新評估合約結構，以防範價格波動和供應中斷，並傾向於簽訂多年期契約，並在必要時增加庫存承諾。

重要的是，關稅也將再形成戰略投資決策。計劃擴大產能、推出新產品或拓展地域的公司必須將成本動態的變化納入其情境規劃和資本配置中。透過深思熟慮的供應鏈重新設計、積極與監管機構溝通以及合約創新，相關人員可以降低風險並維持患者可及性，但這些調整需要有意識的跨職能協調才能有效且永續。

多維細分洞察揭示產品類型、治療層級、管道和最終用戶動態如何影響策略和部署

細分洞察揭示了直接抗病毒市場在關鍵維度上的需求促進因素、臨床特徵和分銷動態的差異。根據產品類型，我們分析了品牌藥和學名藥市場，以及這些差異如何影響定價動態、通路支援以及確保患者接受度和依從性所需的商業夥伴關係關係的性質。品牌藥通常需要在教育、實證和專業分銷方面進行投資，而學名藥則強調成本競爭力、大規模生產和高效的通路滲透。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 擴大全基因型直接抗病毒方案以解決丙型肝炎基因型多樣性
  • 綜合現實世界證據證明 DAA聯合治療的成本效益
  • 重點縮短DAA治療時間，提高病患依從性
  • 全球兒科族群口服 DAA 療法獲得監管部門核准
  • 採用照護現場技術，即時啟動直接抗病毒治療
  • 開發下一代 NS5A 抑制劑以克服抗藥性相關的 HCV 變異
  • 生技公司與世界衛生組織合作，擴大中低收入國家取得直接抗病毒藥物（DAA）的機會

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 直接抗病毒藥物市場（依產品類型）

  • 品牌藥
  • 學名藥

9. 直接抗病毒藥物市場（依治療層級）

  • 聯合治療
  • Ns5A抑制劑
  • Ns5B抑制劑
  • 蛋白酶抑制劑

10. 直接抗病毒藥物市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章直接抗病毒藥物市場（按最終用戶分類）

  • 家庭醫療保健
  • 醫院
  • 專科診所

12. 直接抗病毒藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章直接抗病毒藥物市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 直接抗病毒藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Gilead Sciences, Inc.
    • AbbVie Inc.
    • Merck & Co., Inc.
    • Janssen Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
    • Roche Holding AG
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Cipla Limited
    • Aurobindo Pharma Limited
Product Code: MRR-032A67D91452

The Direct-acting Antiviral Drug Market is projected to grow by USD 33.92 billion at a CAGR of 13.65% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 12.18 billion
Estimated Year [2025] USD 13.87 billion
Forecast Year [2032] USD 33.92 billion
CAGR (%) 13.65%

Contextualizing the clinical, operational, and commercial foundations of direct-acting antiviral therapies to frame strategic decision-making across healthcare stakeholders

The emergence of direct-acting antiviral therapies has permanently reshaped approaches to viral hepatology and infectious disease management, driving meaningful improvements in patient outcomes and redefining the expectations of curative treatment pathways. This introduction establishes the clinical and commercial context for these therapies, focusing on mechanism-of-action innovations, evolving therapeutic classes, and the broader implications for healthcare systems. It also synthesizes recent trends in clinical development where shorter regimens, improved tolerability, and pan-genotypic activity have shifted treatment paradigms and accelerated adoption among specialist clinicians.

From a supply-chain perspective, manufacturing complexity and active pharmaceutical ingredient sourcing have become central considerations for developers and purchasers alike. As a result, quality-by-design manufacturing, biologics-inspired process controls, and strategic supplier relationships are increasingly important for ensuring predictable product availability. Simultaneously, payer perspectives have evolved to emphasize long-term outcomes and cost-of-care reductions, which in turn influence formulary decisions and contracting strategies.

Looking ahead, integration of diagnostics, linkage-to-care programs, and decentralized treatment models will continue to shape the clinical deployment of direct-acting antivirals. Therefore, this introduction frames subsequent sections by outlining the intersections between clinical efficacy, operational deployment, regulatory oversight, and commercial execution that leaders must reconcile when advancing programs from development into routine clinical practice.

How clinical breakthroughs, distribution innovations, and regulatory adaptation are converging to redefine treatment pathways and commercial strategies for antiviral therapies

Transformative shifts are accelerating across the direct-acting antiviral landscape as clinical advances converge with changes in care delivery and commercial strategy. The therapeutic narrative has transitioned from incremental improvements to fundamentally different expectations around cure rates and treatment simplicity, prompting stakeholders to reevaluate standard-of-care pathways and population-level eradication strategies. Concurrently, advances in pharmacology-particularly combination regimens that enhance potency while minimizing resistance risk-have altered clinical trial designs and endpoint selection, leading to more efficient pathways for regulatory acceptance and label expansion.

In parallel, the distribution environment is undergoing a structural evolution. Digital health platforms and telemedicine have reduced barriers to diagnosis and treatment initiation, enabling earlier intervention and expanding the pool of patients who can be treated outside tertiary centers. These shifts have fostered closer collaboration between diagnostic developers, specialty clinics, and community providers, and they have required manufacturers to adopt more flexible commercialization models that support education, adherence, and monitoring within diverse care settings.

Regulatory frameworks have also adapted, with a stronger emphasis on real-world evidence and post-marketing surveillance to monitor long-term outcomes and safety in broader populations. As these transformative forces continue to interact, they create both opportunities and complexities for manufacturers, payers, and providers; stakeholders that proactively align clinical development with scalable delivery models will be best positioned to capture the full value inherent in the next generation of direct-acting antiviral therapies.

Assessing how recent trade policy and tariff developments have reshaped supply chain resilience, sourcing strategy, and procurement practices across antiviral therapeutics

The introduction of tariffs and trade policy adjustments has a cascading effect on pharmaceutical supply chains, procurement strategies, and transactional economics that extend into clinical access and manufacturing planning. Tariff-related costs influence sourcing choices for active pharmaceutical ingredients and excipients, prompting manufacturers to reassess supplier diversification, regional production footprints, and inventory buffers. These operational responses are not merely tactical; they alter lead times for product launch, constrain responsiveness to demand surges, and increase the complexity of contract negotiations with large institutional purchasers and government buyers.

Moreover, tariffs interact with regulatory and quality requirements in ways that complicate sourcing decisions. When suppliers in tariff-impacted jurisdictions also possess regulatory approvals or specialized manufacturing capabilities, firms face trade-offs between cost, compliance, and speed to market. In response, companies increasingly explore regional manufacturing partnerships, tolling arrangements, and vertical integration to mitigate exposure. At the same time, procurement organizations and payers are re-evaluating contracting structures to protect against price volatility and supply disruptions, favoring multi-year agreements or increased inventory commitments when necessary.

Importantly, tariffs also reshape strategic investment decisions. Firms planning capacity expansions, new product rollouts, or geographic entry must incorporate the altered cost dynamics into scenario planning and capital allocation. Through careful supply-chain redesign, proactive regulatory engagement, and contractual innovation, stakeholders can reduce exposure and preserve patient access, although these adjustments require deliberate cross-functional alignment to implement effectively and sustainably.

Multidimensional segmentation insights that illuminate how product type, therapeutic class, channels, and end-user dynamics uniquely influence strategy and deployment

Segmentation insight reveals how demand drivers, clinical profiles, and distribution dynamics differ across key dimensions of the direct-acting antiviral space. Based on Product Type, market is studied across Branded Drugs and Generic Drugs, and this distinction influences pricing dynamics, channel support, and the nature of commercial partnerships required to ensure uptake and adherence. Branded products often require heavier investments in education, real-world evidence generation, and specialty distribution, while Generic Drugs emphasize cost competitiveness, scale manufacturing, and efficient channel penetration.

Based on Therapeutic Class, market is studied across Combination Therapy, Ns5A Inhibitor, Ns5B Inhibitor, and Protease Inhibitor, and each class carries unique clinical positioning, resistance considerations, and regimen complexity that shape prescribing patterns. Combination Therapy often addresses multi-genotype coverage and resistance suppression, whereas class-specific agents may be prioritized where monotherapy still offers clinical advantage or where tolerability is paramount. This therapeutic segmentation has direct consequences for clinical trial design, labeling strategies, and post-approval lifecycle management.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which affects how products are accessed, how adherence is monitored, and how patient support programs are deployed. Hospital Pharmacy channels typically handle more complex cases and institutional contracting, while Online Pharmacy platforms enable broader patient reach and convenience. Based on End User, market is studied across Home Healthcare, Hospitals, and Specialty Clinics, and the end-user mix shapes training requirements, monitoring protocols, and the design of ancillary services required to ensure optimal outcomes. Taken together, these segmentation lenses provide a multidimensional view that informs product positioning, commercialization tactics, and partnership priorities.

Comparative regional dynamics and strategic implications across the Americas, Europe Middle East and Africa, and Asia-Pacific that drive differentiated access and deployment approaches

Regional dynamics have become a decisive factor in shaping development priorities, regulatory engagement strategies, and commercialization planning for direct-acting antivirals. In the Americas, payer-driven contracting, outcomes-based agreements, and robust specialty care networks influence how manufacturers approach formulary access and patient support programs. Regulatory agencies and public health initiatives often prioritize elimination goals, which creates collaborative opportunities between manufacturers and public-sector purchasers to align supply and demand for high-impact interventions.

In Europe, Middle East & Africa, healthcare systems exhibit a breadth of procurement models and budgetary constraints that require nuanced market access strategies. Countries with centralized healthcare procurement may favor negotiated pricing and volume guarantees, whereas regions with heterogeneous payers necessitate adaptable contracting and evidence generation to meet divergent reimbursement thresholds. Meanwhile, supply-chain complexity and capacity variability across parts of Europe, the Middle East, and Africa underscore the need for regional manufacturing partnerships and tailored distribution solutions.

In Asia-Pacific, rapid scale-up of diagnostic and treatment programs, coupled with strong manufacturing capabilities in several countries, creates both competitive and collaborative opportunities. Diverse regulatory pathways and varying degrees of local production capacity make it critical to align product registrations, technology transfers, and commercial launches with country-specific requirements. Across all regions, successful strategies will integrate local clinical engagement, regionally appropriate pricing models, and resilient distribution networks to ensure broad and equitable access to antiviral therapies.

Corporate positioning and competitive dynamics driven by innovation leadership, manufacturing scale, and strategic partnerships that determine sustainable advantage in antiviral therapeutics

Company-level dynamics reflect a mix of innovation leadership, manufacturing scale, and strategic collaborations that collectively determine competitive positioning within the direct-acting antiviral space. Innovative pharmaceutical and biotech companies focus on advancing mechanism-of-action differentiation, expanding pan-genotypic indications, and generating robust safety and real-world effectiveness evidence to sustain clinical preference. These organizations typically invest in integrated ecosystem capabilities-combining clinical affairs, pharmacovigilance, and digital adherence tools-to support durable market access and physician confidence.

Meanwhile, manufacturers with strong generic capabilities emphasize operational excellence, cost optimization, and rapid scale-up to meet demand in price-sensitive markets. Contract manufacturing organizations and tolling partners play a pivotal role in enabling agility, allowing brand and generic players to adjust output in response to procurement cycles and supply shocks. Partnership strategies, including licensing agreements, co-promotion deals, and public-private collaborations, continue to shape the competitive landscape and accelerate treatment uptake in public health initiatives.

Across the corporate landscape, mid-size specialty companies and larger pharma firms differentiate through strategic investments in diagnostics integration, patient support programs, and targeted distribution partnerships. Leadership teams that align clinical differentiation with pragmatic commercialization models and resilient manufacturing networks will be better equipped to navigate regulatory complexity and sustain long-term value creation in this therapeutic area.

Practical strategic actions for industry leaders to align clinical evidence, supply-chain resilience, and channel-specific commercialization to accelerate access and sustain value

Leaders seeking to capitalize on the evolving direct-acting antiviral landscape should adopt a set of pragmatic, high-impact actions that balance clinical credibility with operational resilience. First, integrate clinical development and commercialization planning early so that trial designs generate evidence relevant to payers, guideline committees, and real-world practice. By aligning endpoints, patient populations, and health-economic evidence needs from the outset, organizations can shorten the pathway from approval to meaningful uptake.

Second, strengthen supply-chain resilience through supplier diversification, selective regional manufacturing partnerships, and flexible contract manufacturing arrangements. Scenario planning that incorporates potential trade-policy shifts, raw-material constraints, and demand volatility will enable more adaptive sourcing decisions. Third, tailor distribution and patient-support models to channel realities: design differentiated approaches for Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy that reflect variations in access, adherence, and monitoring requirements. Complement these channel strategies with robust diagnostic linkages and provider education initiatives to ensure appropriate patient selection and follow-through.

Finally, pursue collaborative pricing and contracting approaches with payers, including outcomes-based agreements where appropriate, and invest in data infrastructure to demonstrate value in routine practice. By combining these actions-evidence-aligned development, supply-chain robustness, channel-specific commercialization, and payer collaboration-industry leaders can enhance access, reduce variability in outcomes, and create defensible commercial positions.

A reproducible mixed-methods research design combining primary expert interviews, literature synthesis, supply-chain mapping, and scenario stress testing to ensure robust insights

This research employed a mixed-methods approach that integrates primary qualitative interviews, secondary literature synthesis, and supply-chain and regulatory analysis to produce a comprehensive view of the direct-acting antiviral environment. Primary insights were derived from structured interviews with experienced clinicians, formulary decision-makers, procurement specialists, and industry executives, enabling triangulation of clinical practice patterns, contracting dynamics, and operational challenges. Secondary analysis synthesized peer-reviewed literature, regulatory guidance documents, and publicly available clinical trial outcomes to contextualize therapeutic efficacy, safety profiles, and regulatory trends.

In addition, supply-chain mapping and policy analysis were used to assess sourcing risks, manufacturing dependencies, and the implications of trade-policy shifts. Scenario-based stress testing helped illuminate how different tariff and procurement outcomes could affect operational decisions and stakeholder incentives. Evidence quality checks and cross-validation between internal sources and external subject-matter experts were implemented to ensure the robustness of conclusions.

Transparency in methodology supports reproducibility and allows stakeholders to appraise the fit of insights to their specific contexts. Where appropriate, the research highlights data limitations and recommends areas for targeted follow-up research or bespoke analysis to address organization-specific questions related to access, pricing strategies, and manufacturing expansion planning.

Synthesis of strategic imperatives emphasizing alignment between clinical innovation, operational resilience, and collaborative access models to secure sustainable therapeutic impact

This final synthesis reiterates the central themes that should guide executive decision-making in the direct-acting antiviral domain: therapeutic innovation must be matched with pragmatic strategies for access, delivery, and supply assurance. Clinical advances have created opportunities to rethink treatment pathways and public-health approaches, but capturing the benefits requires careful coordination across development, manufacturing, and market-access functions. Operational resilience-particularly around supplier diversification and manufacturing flexibility-remains essential to protecting product availability and upholding public-health commitments.

Moreover, segmentation and regional nuance matter. Decisions about product type, therapeutic class, distribution channel, and end-user settings will determine the traction a therapy achieves in different healthcare systems and will inform the investments needed across evidence generation, education, and logistics. Finally, collaborative arrangements-whether with payers, public-health agencies, or manufacturing partners-can accelerate access while sharing risk and aligning incentives around long-term outcomes. As organizations translate these conclusions into operational plans, they should prioritize alignment between clinical objectives and commercial realities, ensuring that strategy execution remains patient-centered and resilience-focused.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expanding pan-genotypic direct-acting antiviral regimens addressing hepatitis C genotype diversity
  • 5.2. Integration of real-world evidence demonstrating cost-effectiveness of combination DAA therapies
  • 5.3. Increasing emphasis on shortened DAA treatment durations to improve patient adherence rates
  • 5.4. Regulatory approvals for all-oral DAA therapies in paediatric patient populations worldwide
  • 5.5. Adoption of point-of-care diagnostics to enable immediate linkage to direct-acting antiviral treatment
  • 5.6. Development of next-generation NS5A inhibitors to overcome resistance-associated HCV variants
  • 5.7. Collaborations between biotech firms and global health agencies to expand DAA access in LMICs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Direct-acting Antiviral Drug Market, by Product Type

  • 8.1. Branded Drugs
  • 8.2. Generic Drugs

9. Direct-acting Antiviral Drug Market, by Therapeutic Class

  • 9.1. Combination Therapy
  • 9.2. Ns5A Inhibitor
  • 9.3. Ns5B Inhibitor
  • 9.4. Protease Inhibitor

10. Direct-acting Antiviral Drug Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Direct-acting Antiviral Drug Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Direct-acting Antiviral Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Direct-acting Antiviral Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Direct-acting Antiviral Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Gilead Sciences, Inc.
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Janssen Pharmaceuticals, Inc.
    • 15.3.5. Bristol-Myers Squibb Company
    • 15.3.6. Roche Holding AG
    • 15.3.7. Teva Pharmaceutical Industries Ltd.
    • 15.3.8. Mylan N.V.
    • 15.3.9. Cipla Limited
    • 15.3.10. Aurobindo Pharma Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROTEASE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 89. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 93. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 102. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 104. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. NORTH AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 112. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. LATIN AMERICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. MIDDLE EAST DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. ASEAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GCC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPEAN UNION DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. BRICS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. G7 DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. NATO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 251. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 277. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 282. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 283. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 306. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 307. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)

TABLE 3